Company: LHI
Filing Date: 2025-05-23
Form Type: F-1
Source: 0001213900-25-046955
Chunk: 127

Company: Living Homeopathy International Ltd.
Filing Date: 2025-05-23
Form: F-1
Chunk 127
---
 estimated according to net assessable profit of fiscal year 2023 which was higher than current income tax expense incurred for the fiscal year 2024.

<div align='center'>70</div>

For the year ended March 31, 2023, our net cash generated from operating activities was $1,403,676, which mainly resulted from (i) net income of $1,129,504 and adjusted for non-cash depreciation of $86,164; (ii) decrease in inventories by $216,089 was a result of decreased stock levels in anticipation of sales decline; (iii) increase in accounts payable by $129,121 as our purchased increased; and while partially offset by (i) decrease in income tax payable by $187,860 as provisional tax paid was estimated according to net assessable profit of fiscal year 2022 which was higher than current income tax expense incurred for the fiscal year 2023.

Net cash used in financing activities

Net cash used in financing activities was
$574,414 for the year ended March 31, 2024, which primarily resulted from repayment of $171,087, to Hang Seng Bank Limited in accordance
with the property installment loan agreement between Living Homeopathy Limited and Hang Seng Bank Limited dated October 20, 2021 (the
“Hang Seng Mortgage Loans”), repayment of $78,249 to Mr. To, our Chairman and Chief Executive Officer and dividend
of $325,078 to Mr. To.

Net cash used in financing activities was $3,224,882
for the year ended March 31, 2023, which primarily resulted from repayment of $158,122 to Hang Seng Bank Limited in accordance with the
Hang Seng Mortgage, repayment of $1,563,556 to Mr. To and dividend of $1,503,204 to Mr. To.

Cash flows

The following table sets forth summary of
our cash flows for the six months ended September 30, 2024 and 2023, respectively.

|                                                          |     | For the six months ended 
 September 30,            |      2024 |   |     |   |      2023 |   |
|:---------------------------------------------------------|:----|:-------------------------|----------:|:--|:----|:--|----------:|:--|
| Net cash generated from operating activities             |     | $                        |   362,130 |   |     | $ |   302,